Daily consumption of Reliv Glucaffect for 8 weeks significantly lowered blood glucose and body weight in 50 subjects.
A public change to healthier lifestyles with more physical activity and better nutrition, including caloric restriction, is required to address the obesity epidemic. Weight loss can be achieved by caloric restrictions; current research suggests that this may be achieved by consumption of slowly absorbed carbohydrates owing to the resulting prolonged satiety. Our rationale was to prolong the satiety of overweight volunteers by supplementation with a proprietary formulation Glucaffect which delays absorption of carbohydrates. Glucaffect provides potent alpha-glucosidase inhibitors of herbal source such Pycnogenol, Madeglucyl and various others which obstruct absorption of carbohydrates, such as starch. Fifty overweight subjects received either Glucaffect or an inactive control product for eight weeks. Consumption of Glucaffect was found to statistically significantly lower blood-fasting glucose from baseline 145.3 mg/dL to 101.1 mg/dL (-30.4%) and Hba1c from 7.59% to 6.33% as compared to the control group where values decreased only marginally. The weight and the body mass index (BMI) decreased significantly from an average of 88.5 kg (BMI 26.8 kg/m2) to 81.3 kg (BMI 24.5 kg/m2) as compared to the control group. In conclusion, Glucaffect enabled subjects with metabolic syndrome to achieve healthy BMI and blood glucose levels. Glucaffect was well tolerated and no subject dropped out.
Belcaro
Gianni
G
Irvine3 Vascular Labs and Physiology, Department of Biomedical Sciences, Gabriele D'Annunzio University, Chieti-Pescara, Italy.
Cesarone
Maria
M
Silvia
Errichi
E
Ledda
Andrea
A
Stuard
Stefano
S
G
Vinciguerra
V
Dougall
Mark
M
Cornelli
Umberto
U
Hastings
Carl
C
Schönlau
Frank
F
D000328:Adult; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects*; D015992:Body Mass Index; D050260:Carbohydrate Metabolism / Q000187:drug effects; D005260:Female; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy; D008517:Phytotherapy; D012528:Satiety Response; D015431:Weight Loss / Q000187:drug effects*
D019440:Anti-Obesity Agents; D001786:Blood Glucose; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents